Equillium, Inc. (EQ) 10-Year Financial Performance & Capital Metrics

EQ • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutEquillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Show more

Revenue $41M +13.9%
EBITDA -$8M +43.5%
Net Income -$8M +39.5%
EPS (Diluted) -0.23 +39.5%
Gross Margin 100%
EBITDA Margin -19.79% +50.4%
Operating Margin -20.12% +50.0%
Net Margin -19.63% +46.9%
ROE -38.75% +20.8%
ROIC -804.9% +86.6%
Debt/Equity 0.02 -44.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 94 (top 6%)
✓High quality earnings: Operating CF exceeds net income
✓Efficient asset utilization: 1.6x turnover

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-90.43%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-429.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM-417.11%

ROCE

10Y Avg-46.54%

5Y Avg-55.3%

3Y Avg-60.7%

Latest-39.18%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	15.76M	36.08M	41.09M
Revenue Growth %	-	-	-	-	-	-	1.29%	0.14%
Cost of Goods Sold+	122	6.1K	23K	45K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-122	-6.1K	-23K	-45K	0	15.76M	36.08M	41.09M
Gross Margin %	-	-	-	-	-	1%	1%	1%
Gross Profit Growth %	-	-49.02%	-2.77%	-0.96%	1%	-	1.29%	0.14%
Operating Expenses+	1.71M	8.62M	26.73M	29.5M	37.79M	77.83M	50.61M	49.36M
OpEx % of Revenue	-	-	-	-	-	4.94%	1.4%	1.2%
Selling, General & Admin	378.21K	3.67M	9.09M	10.12M	11.41M	17.24M	13.57M	11.94M
SG&A % of Revenue	-	-	-	-	-	1.09%	0.38%	0.29%
Research & Development	1.33M	4.94M	17.64M	19.38M	26.38M	37.55M	37.04M	37.43M
R&D % of Revenue	-	-	-	-	-	2.38%	1.03%	0.91%
Other Operating Expenses	0	0	0	0	0	23.05M	0	0
Operating Income+	-1.71M	-8.62M	-26.73M	-29.55M	-37.79M	-62.08M	-14.52M	-8.27M
Operating Margin %	-	-	-	-	-	-3.94%	-0.4%	-0.2%
Operating Income Growth %	-	-4.03%	-2.1%	-0.11%	-0.28%	-0.64%	0.77%	0.43%
EBITDA+	-1.71M	-8.61M	-26.7M	-29.5M	-37.71M	-61.96M	-14.4M	-8.13M
EBITDA Margin %	-	-	-	-	-	-3.93%	-0.4%	-0.2%
EBITDA Growth %	-	-4.03%	-2.1%	-0.1%	-0.28%	-0.64%	0.77%	0.44%
D&A (Non-Cash Add-back)	122	6.1K	23K	45K	72K	118K	126K	137K
EBIT	-1.88M	-10.69M	-25.32M	-28.71M	-37.98M	-61.38M	-12.26M	-7.71M
Net Interest Income+	0	-2.22M	1.11M	-623K	-1.02M	-633K	1.84M	1.38M
Interest Income	0	339.62K	1.39M	476K	57K	420K	2.33M	1.38M
Interest Expense	379.38K	2.56M	279K	1.1M	1.07M	1.05M	491K	0
Other Income/Expense	-549.82K	-4.63M	1.13M	-265K	-1.27M	-352K	1.77M	563K
Pretax Income+	-2.26M	-13.25M	-25.6M	-29.81M	-39.05M	-62.43M	-12.76M	-7.71M
Pretax Margin %	-	-	-	-	-	-3.96%	-0.35%	-0.19%
Income Tax+	-2	140.51K	0	0	0	0	580K	361K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1.05%	1.05%
Net Income+	-2.26M	-13.25M	-25.58M	-29.81M	-38.98M	-62.43M	-13.34M	-8.07M
Net Margin %	-	-	-	-	-	-3.96%	-0.37%	-0.2%
Net Income Growth %	-	-4.86%	-0.93%	-0.17%	-0.31%	-0.6%	0.79%	0.4%
Net Income (Continuing)	-2.26M	-13.25M	-25.6M	-29.81M	-39.05M	-62.43M	-13.34M	-8.07M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.19	-1.09	-1.47	-1.46	-1.35	-3.19	-0.38	-0.23
EPS Growth %	-	-4.74%	-0.35%	0.01%	0.08%	-1.36%	0.88%	0.39%
EPS (Basic)	-0.13	-1.09	-1.47	-1.46	-1.35	-3.19	-0.38	-0.23
Diluted Shares Outstanding	11.68M	12.19M	17.38M	20.36M	28.81M	33.73M	34.73M	35.36M
Basic Shares Outstanding	11.68M	12.19M	17.38M	20.36M	28.81M	33.73M	34.73M	35.36M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.15M	67.16M	55.54M	85.17M	83.37M	76.73M	49.35M	24.98M
Cash & Short-Term Investments	7.1M	65.91M	53.14M	82.16M	80.71M	71.02M	40.87M	22.57M
Cash Only	7.1M	28.51M	13.22M	23.98M	50.37M	59.11M	23.22M	18.09M
Short-Term Investments	0	37.4M	39.92M	58.18M	30.34M	11.92M	17.65M	4.49M
Accounts Receivable	0	0	0	0	0	4.11M	6.29M	1.14M
Days Sales Outstanding	-	-	-	-	-	95.26	63.58	10.16
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	8K	235K	429K
Total Non-Current Assets+	2.08K	63.52K	108K	254K	2.04M	1.69M	1.18M	626K
Property, Plant & Equipment	2.08K	63.52K	93K	239K	1.88M	1.58M	1.11M	626K
Fixed Asset Turnover	-	-	-	-	-	9.96x	32.48x	65.65x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	-93K	15K	153K	104K	70K	0
Total Assets+	7.15M	67.16M	55.54M	85.43M	85.41M	78.42M	50.53M	25.6M
Asset Turnover	-	-	-	-	-	0.20x	0.71x	1.61x
Asset Growth %	-	8.39%	-0.17%	0.54%	-0%	-0.08%	-0.36%	-0.49%
Total Current Liabilities+	568.82K	2.03M	3.88M	7.25M	8.91M	32.04M	27.57M	6.36M
Accounts Payable	243.74K	1.12M	1.87M	2.77M	1.23M	3.98M	4.71M	2.68M
Days Payables Outstanding	729.23K	66.93K	29.72K	22.44K	-	-	-	-
Short-Term Debt	0	0	0	1.67M	1.43M	5.71M	0	197K
Deferred Revenue (Current)	0	0	0	0	0	1000K	1000K	0
Other Current Liabilities	0	349.46K	795K	0	3.38M	0	3.64M	2.68M
Current Ratio	12.57x	33.12x	14.30x	11.76x	9.35x	2.40x	1.79x	3.93x
Quick Ratio	12.57x	33.12x	14.30x	11.76x	9.35x	2.40x	1.79x	3.93x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	8.83M	200K	9.81M	8.33M	9.98M	14.44M	384K	187K
Long-Term Debt	8.06M	0	9.68M	8.28M	8.75M	3.24M	0	0
Capital Lease Obligations	0	0	0	0	1.24M	824K	384K	187K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	775.84K	0	127K	54K	0	0	0	0
Total Liabilities	9.4M	2.23M	13.69M	15.57M	18.9M	46.48M	27.96M	6.54M
Total Debt+	8.06M	200K	9.68M	9.94M	11.79M	10.19M	824K	384K
Net Debt	955.31K	-28.31M	-3.54M	-14.04M	-38.58M	-48.92M	-22.39M	-17.7M
Debt / Equity	-	0.00x	0.23x	0.14x	0.18x	0.32x	0.04x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-4.51x	-3.37x	-95.80x	-26.89x	-35.22x	-58.95x	-29.58x	-
Total Equity+	-2.25M	64.94M	41.85M	69.85M	66.5M	31.94M	22.57M	19.06M
Equity Growth %	-	29.83%	-0.36%	0.67%	-0.05%	-0.52%	-0.29%	-0.16%
Book Value per Share	-0.19	5.33	2.41	3.43	2.31	0.95	0.65	0.54
Total Shareholders' Equity	-2.25M	64.94M	41.85M	69.85M	66.5M	31.94M	22.57M	19.06M
Common Stock	124	789	1K	2K	2K	3K	3K	3K
Retained Earnings	-2.26M	-15.51M	-41.11M	-70.92M	-109.98M	-172.41M	-185.74M	-193.81M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	5.28K	21K	-297K	-138K	76K	140K	781K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-662.2K	-7.53M	-22.95M	-24.62M	-32.08M	-8.73M	-21.78M	-19.03M
Operating CF Margin %	-	-	-	-	-	-0.55%	-0.6%	-0.46%
Operating CF Growth %	-	-10.37%	-2.05%	-0.07%	-0.3%	0.73%	-1.49%	0.13%
Net Income	-2.26M	-13.25M	-25.6M	-29.81M	-39.05M	-62.43M	-13.34M	-8.07M
Depreciation & Amortization	122	6.1K	23K	45K	72K	118K	126K	137K
Stock-Based Compensation	0	441.91K	2.25M	3.82M	4.41M	4.84M	4M	0
Deferred Taxes	0	0	0	-269K	554K	0	0	0
Other Non-Cash Items	1.17M	4.98M	-337K	341K	237K	48.72M	-10.03M	-11.94M
Working Capital Changes	434.63K	301K	713K	1.25M	1.7M	19K	-2.55M	842K
Change in Receivables	0	0	0	0	0	-2.84M	-897K	3.73M
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	842.72K	775K	894K	-1.58M	2.51M	723K	-2M
Cash from Investing+	-2.2K	-37.43M	-2.17M	-18.59M	27.41M	18.68M	-4.76M	13.81M
Capital Expenditures	-2.2K	-34.86K	-74K	-202K	-57K	-279K	-50K	-85K
CapEx % of Revenue	-	-	-	-	-	0.02%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0
Cash from Financing+	7.77M	66.37M	9.84M	53.95M	31.06M	-1.22M	-9.23M	164K
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	291.56K	111K	163K	1.15M	214K	165K	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-664.4K	-7.56M	-23.02M	-24.83M	-32.14M	-9.01M	-21.83M	-19.11M
FCF Margin %	-	-	-	-	-	-0.57%	-0.61%	-0.47%
FCF Growth %	-	-10.38%	-2.04%	-0.08%	-0.29%	0.72%	-1.42%	0.12%
FCF per Share	-0.06	-0.62	-1.32	-1.22	-1.12	-0.27	-0.63	-0.54
FCF Conversion (FCF/Net Income)	0.29x	0.57x	0.90x	0.83x	0.82x	0.14x	1.63x	2.36x
Interest Paid	0	0	142K	0	0	847K	946K	0
Taxes Paid	0	0	0	0	0	0	580K	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-42.28%	-47.9%	-53.38%	-57.17%	-126.83%	-48.92%	-38.75%
Return on Invested Capital (ROIC)	-	-36.58%	-53.5%	-47.09%	-67.68%	-850.51%	-6017.4%	-804.9%
Gross Margin	-	-	-	-	-	100%	100%	100%
Net Margin	-	-	-	-	-	-396.14%	-36.96%	-19.63%
Debt / Equity	-	0.00x	0.23x	0.14x	0.18x	0.32x	0.04x	0.02x
Interest Coverage	-4.51x	-3.37x	-95.80x	-26.89x	-35.22x	-58.95x	-29.58x	-
FCF Conversion	0.29x	0.57x	0.90x	0.83x	0.82x	0.14x	1.63x	2.36x
Revenue Growth	-	-	-	-	-	-	128.97%	13.89%

Frequently Asked Questions

Growth & Financials

Equillium, Inc. (EQ) reported $4.4M in revenue for fiscal year 2024.

Equillium, Inc. (EQ) grew revenue by 13.9% over the past year. This is steady growth.

Equillium, Inc. (EQ) reported a net loss of $24.4M for fiscal year 2024.

Dividend & Returns

Equillium, Inc. (EQ) has a return on equity (ROE) of -38.8%. Negative ROE indicates the company is unprofitable.

Equillium, Inc. (EQ) had negative free cash flow of $22.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Equillium, Inc. (EQ) 10-Year Financial Performance & Capital Metrics

EQ • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $41M +13.9%
EBITDA -$8M +43.5%
Net Income -$8M +39.5%
EPS (Diluted) -0.23 +39.5%
Gross Margin 100%
EBITDA Margin -19.79% +50.4%
Operating Margin -20.12% +50.0%
Net Margin -19.63% +46.9%
ROE -38.75% +20.8%
ROIC -804.9% +86.6%
Debt/Equity 0.02 -44.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 94 (top 6%)
✓High quality earnings: Operating CF exceeds net income
✓Efficient asset utilization: 1.6x turnover

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-90.43%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-429.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM-417.11%

ROCE

10Y Avg-46.54%

5Y Avg-55.3%

3Y Avg-60.7%

Latest-39.18%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	15.76M	36.08M	41.09M
Revenue Growth %	-	-	-	-	-	-	1.29%	0.14%
Cost of Goods Sold+	122	6.1K	23K	45K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-122	-6.1K	-23K	-45K	0	15.76M	36.08M	41.09M
Gross Margin %	-	-	-	-	-	1%	1%	1%
Gross Profit Growth %	-	-49.02%	-2.77%	-0.96%	1%	-	1.29%	0.14%
Operating Expenses+	1.71M	8.62M	26.73M	29.5M	37.79M	77.83M	50.61M	49.36M
OpEx % of Revenue	-	-	-	-	-	4.94%	1.4%	1.2%
Selling, General & Admin	378.21K	3.67M	9.09M	10.12M	11.41M	17.24M	13.57M	11.94M
SG&A % of Revenue	-	-	-	-	-	1.09%	0.38%	0.29%
Research & Development	1.33M	4.94M	17.64M	19.38M	26.38M	37.55M	37.04M	37.43M
R&D % of Revenue	-	-	-	-	-	2.38%	1.03%	0.91%
Other Operating Expenses	0	0	0	0	0	23.05M	0	0
Operating Income+	-1.71M	-8.62M	-26.73M	-29.55M	-37.79M	-62.08M	-14.52M	-8.27M
Operating Margin %	-	-	-	-	-	-3.94%	-0.4%	-0.2%
Operating Income Growth %	-	-4.03%	-2.1%	-0.11%	-0.28%	-0.64%	0.77%	0.43%
EBITDA+	-1.71M	-8.61M	-26.7M	-29.5M	-37.71M	-61.96M	-14.4M	-8.13M
EBITDA Margin %	-	-	-	-	-	-3.93%	-0.4%	-0.2%
EBITDA Growth %	-	-4.03%	-2.1%	-0.1%	-0.28%	-0.64%	0.77%	0.44%
D&A (Non-Cash Add-back)	122	6.1K	23K	45K	72K	118K	126K	137K
EBIT	-1.88M	-10.69M	-25.32M	-28.71M	-37.98M	-61.38M	-12.26M	-7.71M
Net Interest Income+	0	-2.22M	1.11M	-623K	-1.02M	-633K	1.84M	1.38M
Interest Income	0	339.62K	1.39M	476K	57K	420K	2.33M	1.38M
Interest Expense	379.38K	2.56M	279K	1.1M	1.07M	1.05M	491K	0
Other Income/Expense	-549.82K	-4.63M	1.13M	-265K	-1.27M	-352K	1.77M	563K
Pretax Income+	-2.26M	-13.25M	-25.6M	-29.81M	-39.05M	-62.43M	-12.76M	-7.71M
Pretax Margin %	-	-	-	-	-	-3.96%	-0.35%	-0.19%
Income Tax+	-2	140.51K	0	0	0	0	580K	361K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1.05%	1.05%
Net Income+	-2.26M	-13.25M	-25.58M	-29.81M	-38.98M	-62.43M	-13.34M	-8.07M
Net Margin %	-	-	-	-	-	-3.96%	-0.37%	-0.2%
Net Income Growth %	-	-4.86%	-0.93%	-0.17%	-0.31%	-0.6%	0.79%	0.4%
Net Income (Continuing)	-2.26M	-13.25M	-25.6M	-29.81M	-39.05M	-62.43M	-13.34M	-8.07M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.19	-1.09	-1.47	-1.46	-1.35	-3.19	-0.38	-0.23
EPS Growth %	-	-4.74%	-0.35%	0.01%	0.08%	-1.36%	0.88%	0.39%
EPS (Basic)	-0.13	-1.09	-1.47	-1.46	-1.35	-3.19	-0.38	-0.23
Diluted Shares Outstanding	11.68M	12.19M	17.38M	20.36M	28.81M	33.73M	34.73M	35.36M
Basic Shares Outstanding	11.68M	12.19M	17.38M	20.36M	28.81M	33.73M	34.73M	35.36M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.15M	67.16M	55.54M	85.17M	83.37M	76.73M	49.35M	24.98M
Cash & Short-Term Investments	7.1M	65.91M	53.14M	82.16M	80.71M	71.02M	40.87M	22.57M
Cash Only	7.1M	28.51M	13.22M	23.98M	50.37M	59.11M	23.22M	18.09M
Short-Term Investments	0	37.4M	39.92M	58.18M	30.34M	11.92M	17.65M	4.49M
Accounts Receivable	0	0	0	0	0	4.11M	6.29M	1.14M
Days Sales Outstanding	-	-	-	-	-	95.26	63.58	10.16
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	8K	235K	429K
Total Non-Current Assets+	2.08K	63.52K	108K	254K	2.04M	1.69M	1.18M	626K
Property, Plant & Equipment	2.08K	63.52K	93K	239K	1.88M	1.58M	1.11M	626K
Fixed Asset Turnover	-	-	-	-	-	9.96x	32.48x	65.65x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	-93K	15K	153K	104K	70K	0
Total Assets+	7.15M	67.16M	55.54M	85.43M	85.41M	78.42M	50.53M	25.6M
Asset Turnover	-	-	-	-	-	0.20x	0.71x	1.61x
Asset Growth %	-	8.39%	-0.17%	0.54%	-0%	-0.08%	-0.36%	-0.49%
Total Current Liabilities+	568.82K	2.03M	3.88M	7.25M	8.91M	32.04M	27.57M	6.36M
Accounts Payable	243.74K	1.12M	1.87M	2.77M	1.23M	3.98M	4.71M	2.68M
Days Payables Outstanding	729.23K	66.93K	29.72K	22.44K	-	-	-	-
Short-Term Debt	0	0	0	1.67M	1.43M	5.71M	0	197K
Deferred Revenue (Current)	0	0	0	0	0	1000K	1000K	0
Other Current Liabilities	0	349.46K	795K	0	3.38M	0	3.64M	2.68M
Current Ratio	12.57x	33.12x	14.30x	11.76x	9.35x	2.40x	1.79x	3.93x
Quick Ratio	12.57x	33.12x	14.30x	11.76x	9.35x	2.40x	1.79x	3.93x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	8.83M	200K	9.81M	8.33M	9.98M	14.44M	384K	187K
Long-Term Debt	8.06M	0	9.68M	8.28M	8.75M	3.24M	0	0
Capital Lease Obligations	0	0	0	0	1.24M	824K	384K	187K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	775.84K	0	127K	54K	0	0	0	0
Total Liabilities	9.4M	2.23M	13.69M	15.57M	18.9M	46.48M	27.96M	6.54M
Total Debt+	8.06M	200K	9.68M	9.94M	11.79M	10.19M	824K	384K
Net Debt	955.31K	-28.31M	-3.54M	-14.04M	-38.58M	-48.92M	-22.39M	-17.7M
Debt / Equity	-	0.00x	0.23x	0.14x	0.18x	0.32x	0.04x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-4.51x	-3.37x	-95.80x	-26.89x	-35.22x	-58.95x	-29.58x	-
Total Equity+	-2.25M	64.94M	41.85M	69.85M	66.5M	31.94M	22.57M	19.06M
Equity Growth %	-	29.83%	-0.36%	0.67%	-0.05%	-0.52%	-0.29%	-0.16%
Book Value per Share	-0.19	5.33	2.41	3.43	2.31	0.95	0.65	0.54
Total Shareholders' Equity	-2.25M	64.94M	41.85M	69.85M	66.5M	31.94M	22.57M	19.06M
Common Stock	124	789	1K	2K	2K	3K	3K	3K
Retained Earnings	-2.26M	-15.51M	-41.11M	-70.92M	-109.98M	-172.41M	-185.74M	-193.81M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	5.28K	21K	-297K	-138K	76K	140K	781K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-662.2K	-7.53M	-22.95M	-24.62M	-32.08M	-8.73M	-21.78M	-19.03M
Operating CF Margin %	-	-	-	-	-	-0.55%	-0.6%	-0.46%
Operating CF Growth %	-	-10.37%	-2.05%	-0.07%	-0.3%	0.73%	-1.49%	0.13%
Net Income	-2.26M	-13.25M	-25.6M	-29.81M	-39.05M	-62.43M	-13.34M	-8.07M
Depreciation & Amortization	122	6.1K	23K	45K	72K	118K	126K	137K
Stock-Based Compensation	0	441.91K	2.25M	3.82M	4.41M	4.84M	4M	0
Deferred Taxes	0	0	0	-269K	554K	0	0	0
Other Non-Cash Items	1.17M	4.98M	-337K	341K	237K	48.72M	-10.03M	-11.94M
Working Capital Changes	434.63K	301K	713K	1.25M	1.7M	19K	-2.55M	842K
Change in Receivables	0	0	0	0	0	-2.84M	-897K	3.73M
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	842.72K	775K	894K	-1.58M	2.51M	723K	-2M
Cash from Investing+	-2.2K	-37.43M	-2.17M	-18.59M	27.41M	18.68M	-4.76M	13.81M
Capital Expenditures	-2.2K	-34.86K	-74K	-202K	-57K	-279K	-50K	-85K
CapEx % of Revenue	-	-	-	-	-	0.02%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0
Cash from Financing+	7.77M	66.37M	9.84M	53.95M	31.06M	-1.22M	-9.23M	164K
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	291.56K	111K	163K	1.15M	214K	165K	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-664.4K	-7.56M	-23.02M	-24.83M	-32.14M	-9.01M	-21.83M	-19.11M
FCF Margin %	-	-	-	-	-	-0.57%	-0.61%	-0.47%
FCF Growth %	-	-10.38%	-2.04%	-0.08%	-0.29%	0.72%	-1.42%	0.12%
FCF per Share	-0.06	-0.62	-1.32	-1.22	-1.12	-0.27	-0.63	-0.54
FCF Conversion (FCF/Net Income)	0.29x	0.57x	0.90x	0.83x	0.82x	0.14x	1.63x	2.36x
Interest Paid	0	0	142K	0	0	847K	946K	0
Taxes Paid	0	0	0	0	0	0	580K	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-42.28%	-47.9%	-53.38%	-57.17%	-126.83%	-48.92%	-38.75%
Return on Invested Capital (ROIC)	-	-36.58%	-53.5%	-47.09%	-67.68%	-850.51%	-6017.4%	-804.9%
Gross Margin	-	-	-	-	-	100%	100%	100%
Net Margin	-	-	-	-	-	-396.14%	-36.96%	-19.63%
Debt / Equity	-	0.00x	0.23x	0.14x	0.18x	0.32x	0.04x	0.02x
Interest Coverage	-4.51x	-3.37x	-95.80x	-26.89x	-35.22x	-58.95x	-29.58x	-
FCF Conversion	0.29x	0.57x	0.90x	0.83x	0.82x	0.14x	1.63x	2.36x
Revenue Growth	-	-	-	-	-	-	128.97%	13.89%

Frequently Asked Questions

Growth & Financials

Equillium, Inc. (EQ) reported $4.4M in revenue for fiscal year 2024.

Equillium, Inc. (EQ) grew revenue by 13.9% over the past year. This is steady growth.

Equillium, Inc. (EQ) reported a net loss of $24.4M for fiscal year 2024.

Dividend & Returns

Equillium, Inc. (EQ) has a return on equity (ROE) of -38.8%. Negative ROE indicates the company is unprofitable.

Equillium, Inc. (EQ) had negative free cash flow of $22.9M in fiscal year 2024, likely due to heavy capital investments.